SCHEMBL26806784

SCHEMBL26806784

CCOc1cc(-c2ccccc2C(C)C)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.41
▸ MAPT P10636 1/20 0.39
▸ PIK3C2B O00750 1/20 0.39
▸ PIK3C2G O75747 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ PKM P14618 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HTR6 P50406 1/20 0.36
▸ F2 P00734 1/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ PRSS2 P07478 1/20 0.36
▸ PRSS3 P35030 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26806783 0.90 POLB (0.41) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806794 0.90 POLB (0.38) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806787 0.90 PTGS1 (0.40) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806726 0.89 POLB (0.43) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL29566848 0.89 POLB (0.37) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806781 0.89 POLB (0.37) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL24309523 0.88 POLB (0.36) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL29566755 0.88 POLB (0.36) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806791 0.88 POLB (0.36) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2
SCHEMBL26806788 0.88 LMNA (0.37) POLBMAPTPIK3C2BPIK3C2GSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3593/4885MAPT 4864/4885PIK3C2B 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback